Treatment Information

Back

Ovarian Cancer treatment details. Chemotherapy.

Vall d’Hebron University Hospital, Barcelona, Spain.

Survival: monthsCountry:Spain
Toxiciy Grade:5City/State/Province:Barcelona
Treatments:ChemotherapyHospital:Vall d’Hebron University Hospital
Drugs:Journal:Link
Date:Mar 2013

Description:

Patients:
This phase 2 study involved 295 refractory/recurrent ovarian cancer patients with a median age of 58 years.

Treatment:
Patients were treated with the chemotherapy agent called trabectedin.

Toxicities:
There were two treatment-related deaths due to multi organ failure and heart attack. Grade 4 neutropenia and liver toxicity, and grade 3 fatigue, nausea, and vomiting were also reported.

Results:
The median overall survival was 17.1 months.

Support:
This study was supported by PharmaMar, makers of Yondelis (brand name for trabectedin).

Correspondence: Dr. Jose Maria del Campo; email: [email protected]



Back